HIV/AIDS人群结核分枝杆菌感染现状及预防性治疗研究进展

doi:10.19983/j.issn.2096-8493.20220155

摘要/Abstract

摘要：

结核分枝杆菌(Mycobacterium tuberculosis,MTB)合并感染以及结核病的发生严重影响人类免疫缺陷病毒(human immunodeficiency virus, HIV)感染者及获得性免疫缺陷综合征(acquired immune deficiency syndrome, AIDS)患者的生存质量。加强对MTB/HIV双重感染人群MTB的感染控制及结核病的预防干预,对于两大传染病的防控都有重要的实践意义。笔者针对HIV/AIDS人群MTB感染现状和结核病预防性治疗研究进展进行综述,探讨我国HIV/AIDS人群开展结核病防控亟待加强的重点内容和工作思路。

关键词: 分枝杆菌,结核, 获得性免疫缺陷综合征, 预防和防护用药

Abstract:

The co-infection of Mycobacterium tuberculosis (MTB) and the occurrence of tuberculosis (TB) seriously affect the quality of life among patients with human immunodeficiency virus/acquired immune-deficiency syndrome (HIV/AIDS). It is of great practical significance to strengthen the control of MTB infection and preventive treatment of TB among MTB/HIV co-infected people for the prevention and control of the above two major infectious diseases. The current situation of MTB infection in HIV/AIDS population and research progress in TB preventive treatment were reviewed, to explore the key content and ideas of TB prevention and control in HIV/AIDS population in China.

Key words: Mycobacterium tuberculosis, Acquired immune deficiency syndrome, Protective agents

中图分类号:

R512.91
R52

曹雪芳, 何勇鹏, 高磊. HIV/AIDS人群结核分枝杆菌感染现状及预防性治疗研究进展[J]. 结核与肺部疾病杂志, 2022, 3(6): 511-516. doi: 10.19983/j.issn.2096-8493.20220155

Cao Xuefang, He Yongpeng, Gao Lei. Research progress in current situation of Mycobacterium tuberculosis infection and preventive treatment in HIV/AIDS population[J]. Journal of Tuberculosis and Lung Disease, 2022, 3(6): 511-516. doi: 10.19983/j.issn.2096-8493.20220155

参考文献 45

[1]	World Health Organization. Key facts HIV[R/OL]. [2012-03-27]. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/key-facts-hiv-2021-26july2022.pdf.
[2]	Geremew D, Endalamaw A, Negash M, et al. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. BMC Infect Dis, 2019, 19(1):405. doi:10.1186/s12879-019-4031-2. doi: 10.1186/s12879-019-4031-2 URL pmid: 31077133
[3]	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[4]	World Health Organization. WHO consolidated guidelines on tuberculosis module 1: prevention tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[5]	何纳. 中国艾滋病流行病学研究新进展. 中华疾病控制杂志, 2021, 25(12)1365-1368,1480. doi:10.16462/j.cnki.zhjbkz.2021.12.001. doi: 10.16462/j.cnki.zhjbkz.2021.12.001 URL
[6]	沈佳胤, 卢洪洲. 艾滋病合并结核病的防治研究进展. 中国艾滋病性病, 2015, 21(6):543-546. doi:10.13419/j.cnki.aids.2015.06.30. doi: 10.13419/j.cnki.aids.2015.06.30 URL
[7]	郑志刚, 耿文奎, 陆珍珍, 等. 艾滋病病毒与结核分枝杆菌双重感染对死亡的影响. 中华流行病学杂志, 2018, 39(10):1362-1367. doi:10.3760/cma.j.issn.0254-6450.2018.10.014. doi: 10.3760/cma.j.issn.0254-6450.2018.10.014 URL
[8]	Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection. Am Fam Physician, 2014, 89(11):889-896. pmid: 25077395
[9]	World Health Organization. Guidelines on the management of latent tuberculosis infection[EB/OL].[2017-02-15]. http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_eng.pdf?ua=1.
[10]	Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr, 2011, 56(3):230-238. doi:10.1097/QAI.0b013e31820b07ab. doi: 10.1097/QAI.0b013e31820b07ab URL pmid: 21239993
[11]	Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet, 2014, 384(9944):682-690. doi:10.1016/S0140-6736(14)60162-8. doi: 10.1016/S0140-6736(14)60162-8 URL pmid: 24835842
[12]	Singh R, Fatima N, Shukla I, et al. Evaluation of role of interferon gamma release assays in the diagnosis of latent tuberculosis in human immunodeficiency virus-infected patients. Indian J Sex Transm Dis AIDS, 2021, 42(2):111-117. doi:10.4103/ijstd.IJSTD_16_20. doi: 10.4103/ijstd.IJSTD_16_20 URL pmid: 34909614
[13]	Hamada Y, Getahun H, Tadesse BT, et al. HIV-associated tuberculosis. Int J STD AIDS, 2021, 32(9):780-790. doi:10.1177/0956462421992257. doi: 10.1177/0956462421992257 URL pmid: 33612015
[14]	World Health Organization. Guidelines on intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in res ourceconstrained setting. Geneva:World Health Organization, 2011.
[15]	Gupta S, Granich R, Date A, et al. Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries. Int J Tuberc Lung Dis, 2014, 18(10): 1149-1158. doi:10.5588/ijtld.13.0889. doi: 10.5588/ijtld.13.0889 URL pmid: 25216827
[16]	Adams LV, Talbot EA, Odato K, et al. Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews. BMC Infect Dis, 2014, 14: 281. doi:10.1186/1471-2334-14-281. doi: 10.1186/1471-2334-14-281 URL pmid: 24886159
[17]	Moolphate S, Lawpoolsri S, Pungrassami P, et al. Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. Glob J Health Sci, 2013, 5(4): 60-70. doi:10.5539/gjhs.v5n4p60. doi: 10.5539/gjhs.v5n4p60 URL pmid: 23777722
[18]	Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med, 1997, 337(12): 801-808. doi:10.1056/NEJM1997 09183371201. doi: 10.1056/NEJM199709183371201 URL
[19]	Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet, 1993, 342(8866): 268-272. doi:10.1016/0140- 6736(93)91817-6.
[20]	Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis, 2014, 14(4):281-290. doi:10.1016/S1473-3099(13)70692-3. doi: 10.1016/S1473-3099(13)70692-3 URL pmid: 24602844
[21]	TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med, 2015, 373(9): 808-822. doi:10.1056/NEJMoa1507198. doi: 10.1056/NEJMoa1507198 URL
[22]	INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med, 2015, 373(9):795-807. doi:10.1056/NEJMoa1506816. doi: 10.1056/NEJMoa1506816 URL
[23]	WHO Policy on Collaborative TB/HIV Activities: Guidelines for National Programmes and Other Stakeholders. Geneva:World Health Organization, 2012.
[24]	Geremew D, Endalamaw A, Negash M, et al. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. BMC Infect Dis, 2019, 19(1):405. doi:10.1186/s12879-019-4031-2. doi: 10.1186/s12879-019-4031-2 URL pmid: 31077133
[25]	Dowdy DW, Golub JE, Saraceni V, et al. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. J Acquir Immune Defic Syndr, 2014, 66(5):552-558. doi:10.1097/QAI.0000000000000219. doi: 10.1097/QAI.0000000000000219 URL pmid: 24853308
[26]	World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization, 2014.
[27]	Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health, 2017, 5(11):e1080-e1089. doi:10.1016/S2214-109X(17)30372-8. doi: 10.1016/S2214-109X(17)30372-8 URL
[28]	Zunza M, Gray DM, Young T, et al. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Infectious Diseases Group, editor. Cochrane Database Syst Rev, 2017, 8(8):CD006418. doi:10.1002/14651858.CD006418. doi: 10.1002/14651858.CD006418 URL
[29]	Chaisson LH, Saraceni V, Cohn S, et al. CD4⁺ cell count stratification to guide tuberculosis preventive therapy for people living with HIV. AIDS, 2020, 34(1):139-147. doi:10.1097/QAD.0000000000002398. doi: 10.1097/QAD.0000000000002398 URL pmid: 31634189
[30]	Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane HIV/AIDS Group, editor.Cochrane Database Syst Rev, 2010, 2010(1): CD000171. doi:10.1002/14651858.CD000171. doi: 10.1002/14651858.CD000171 URL
[31]	Samandari T, Agizew TB, Nyirenda S, et al. Tuberculosis incidence after 36 months’ isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS, 2015, 29(3): 351-359. doi:10.1097/QAD.0000000000000535. doi: 10.1097/QAD.0000000000000535 URL pmid: 25686683
[32]	Stagg HR, Zenner D, Harris RJ, et al. Treatment of Latent Tuberculosis Infection: A Network Meta-analysis. Ann Intern Med, 2014, 161(6):419-428. doi:10.7326/M14-1019. doi: 10.7326/M14-1019 URL pmid: 25111745
[33]	Zenner D, Beer N, Harris RJ, et al. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. Ann Intern Med, 2017, 167(4):248-255. doi:10.7326/M17-0609. doi: 10.7326/M17-0609 URL pmid: 28761946
[34]	Campbell JR, Al-Jahdali H, Bah B, et al. Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. Clin Infect Dis, 2021, 73(9):e3545-e3554. doi:10.1093/cid/ciaa1169. doi: 10.1093/cid/ciaa1169 URL
[35]	World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization, 2015.
[36]	Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis, 2007, 45(6):715-722. doi:10.1086/520983. doi: 10.1086/520983 URL pmid: 17712755
[37]	Sterling TR, Scott NA, Miro JM, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS, 2016, 30(10):1607-1615. doi:10.1097/QAD.0000000000001098. doi: 10.1097/QAD.0000000000001098 URL pmid: 27243774
[38]	Churchyard G, Cárdenas V, Chihota V, et al. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection: A Randomized Trial. Ann Intern Med, 2021, 174(10):1367-1376. doi:10.7326/M20-7577. doi: 10.7326/M20-7577 URL pmid: 34424730
[39]	Swindells S, Ramchandani R, Gupta A, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med, 2019, 380 (11):1001-1011. doi:10.1056/NEJMoa1806808. doi: 10.1056/NEJMoa1806808 URL
[40]	Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis, 1999, 3(10):847-850. pmid: 10524579
[41]	Kalk E, Heekes A, Mehta U, et al. Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data. Clin Infect Dis, 2020, 71(8):e351-e358. doi:10.1093/cid/ciz1224. doi: 10.1093/cid/ciz1224 URL pmid: 31900473
[42]	Geremew D, Melku M, Endalamaw A, et al. Tuberculosis and its association with CD4⁺ T cell count among adult HIV positive patients in Ethiopian settings: a systematic review and meta-analysis. BMC Infect Dis, 2020, 20(1):325. doi:10.1186/s12879-020-05040-4. doi: 10.1186/s12879-020-05040-4 URL pmid: 32380957
[43]	中华医学会感染病学分会艾滋病学组, 中华医学会热带病与寄生虫学分会艾滋病学组. HIV合并结核分枝杆菌感染诊治专家共识. 中华临床感染病杂志, 2017, 10(2):81-90. doi:10.3760/cma.j.issn.1674-2397.2017.02.001. doi: 10.3760/cma.j.issn.1674-2397.2017.02.001 URL
[44]	关于印发《江苏省遏制艾滋病传播实施方案(2019—2022年)》的通知.苏卫疾控〔2019〕53号. 2020-01-03.
[45]	王倪, 刘二勇, 马艳, 等. HIV感染者抗结核预防治疗试点实施及效果分析. 中国艾滋病性病, 2018, 24(10):986-989. doi:10.13419/j.cnki.aids.2018.10.07. doi: 10.13419/j.cnki.aids.2018.10.07 URL